Rheumatology

Each 1-SD increment in HDL-C level was associated with a 14% higher risk of fractures in cohort study of approximately 16,000 community-dwelling healthy adults.

Improved patient-reported outcomes were observed in patients who used mind-body interventions, such as cognitive behavioral therapy and yoga, and were effective for managing IBS and fibromyalgia.

Intervention strategies that focus on the reduction of catastrophic thinking in addition to physical exercise may be beneficial for patients with fibromyalgia.

When is the right time to taper glucocorticoids and what is the correct approach? Take this quiz to test your knowledge.

Studying quality care markers can help clinicians understand treatment variations and non-adherence in patients with rheumatoid arthritis, which may improve outcomes and decrease financial burdens.

Hydroxychloroquine dosing higher than 6 mg/kg was associated with a 15-year risk of nearly 22%, while retinopathy risk with shorter duration of use was significantly lower.

In this Q&A, Mireia Moreno, MD, discussed the findings of a study that evaluated the influence of HLA-B27 in the phenotypical expression of peripheral spondyloarthritis (pSpA), including psoriatic arthritis, which is the most well-defined pSpA.

The etanercept biosimilar, YLB113 (Nepexto), maintained a favorable efficacy, safety, and immunogenicity profile through week 96.

In the post-hoc analysis, an association between cumulative local joint swelling and progression of radiographic damage in the same joint was observed in patients with rheumatoid arthritis.

Despite EULAR recommendations encouraging the tapering of glucocorticoids and the rapidly expanding treatment options for patients with rheumatoid arthritis, glucocorticoids are still commonly prescribed to reduce inflammation and manage disease activity.

There has been a rapid uptake of Janus kinase (JAK) inhibitors for the treatment of rheumatoid arthritis. How much do you know about this class of drugs? Test your knowledge with this quiz.

Disease-dependent factors, such as a history of adverse reactions to bio-originators and disease activity, influenced patients' acceptance of switching from a biologic to a biosimilar.

The cross-sectional study evaluated the relationship between the mediating variable, distress, and pain and functionality in patients with fibromyalgia after controlling for age, gender, and income.

“Although the evolution of COVID-19 is favorable worldwide, multiple variables related to psychological health and the response to stressors seem to have triggered symptomatologic responses in fibromyalgia patients,” investigators stated.

Patients with psoriatic arthritis who achieve minimal disease activity during the first year of diagnosis are shown to experience better health-related quality of life, improved mental wellbeing, and reduced fatigue.

Although high intensity resistance training did not improve mood in women with fibromyalgia, anger decreased during the 8-week, supervised intervention program.

Although the incidence rates were similar among those treated with TNFi and biologics-naïve patients, patients with psoriatic arthritis had a 35% increased risk when compared with the general population.

Results from the MUST trial reported that ustekinumab monotherapy was just as effective in treating psoriatic arthritis as treatment with ustekinumab plus methotrexate.

Although patients with inflammatory conditions reported positive attitudes towards biologic treatment, they were far less familiar with biosimilars, indicating the need for clinicians to provide patient education more effectively.

Given the growing evidence that patients with gout are at an increased risk of developing cardiovascular disease, accurately screening patients and identifying potential risk factors is of critical importance.

At the 6-month mark, there were no significant differences between the treatment groups regarding composite score-defined remission.

It is well-known that rheumatoid arthritis patients have a heightened risk of cardiovascular events, but how do RA treatments affect this risk? Test your knowledge with this quiz.

A group of investigators, researchers and policymakers discuss the issues, innovations and aspirations that may define 2023 advances.

Take a few minutes to review the most noteworthy studies published on Rheumatology Network in 2022.

Alfredo Aguirre, MD, discusses the latest data regarding lupus this year at the American College of Rheumatology (ACR) Convergence 2022, trends in lupus management, and the importance of remission in lupus.

Ayman Askari, MD, discusses the recent trends in rheumatoid arthritis, studies presented at the American College of Rheumatology (ACR) Convergence 2022, and the pressing issues that face rheumatologists moving into 2023.

Current literature is trending towards exploring the impact of complementary and alternative treatments for fibromyalgia and an overall focus on multidisciplinary care.

Take 5 minutes to catch up on Rheumatology Network's top articles from December 2022.

Nehad Soloman, MD, provides final thoughts on what rheumatologists can look forward to in 2023 for rheumatic disease management.

An expert in rheumatology highlights challenges faced in the rheumatology workforce and how to optimize addressing these issues going forward.